Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials
- 1 June 2003
- journal article
- clinical trial
- Published by Elsevier in European Journal Of Cancer
- Vol. 39 (9) , 1228-1233
- https://doi.org/10.1016/s0959-8049(03)00199-0
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American TrialJournal of Clinical Oncology, 2002
- Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine TreatmentJournal of Clinical Oncology, 2002
- Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breastJournal of Surgical Oncology, 2001
- ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women — prospective combined analysis of two multicenter trialsEuropean Journal Of Cancer, 2001
- Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast CancerJNCI Journal of the National Cancer Institute, 1995
- Use of tamoxifen for breast cancer: twenty-eight years later.Journal of Clinical Oncology, 1995
- The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growthCancer Chemotherapy and Pharmacology, 1994